The world’s biggest auto manufacturer said it will produce 800,000 units in November and suspend operations at several of its plants in Japan due to the impact of supply constraints.
The oral drug, nilotinib, is used to treat chronic myeloid leukemia, and may be made in Egypt, Guatemala, Indonesia, Morocco, Pakistan, the Philippines and Tunisia.
Where OEMs in the past could concentrate on securing supply of expensive components, now they have to think about everything that goes into production, including raw materials, too.